| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical and preclinical and data on the RaniPill® capsule, the company's oral delivery platform, at Digestive Disease Week® (DDW) taking place both virtually and in-person on May 18-21, 2024 in Washington, DC.
Details of the presentations are as follows:
Abstract Title: An Orally Administered Robotic Pill (RP) Reliably and Safely Delivers an Ustekinumab Biosimilar RT-111 with High Bioavailability Relative to Subcutaneous (SC) Ustekinumab in Healthy Human Participants
Session Type: Late-Breaking Oral Presentation
Session Title: IMIBD Late Breakers and Innovations in IBD
Session Date & Time: May 19, 2024 from 2:00 – 3:30 EDT
Presentation Time: 3:00 PM to 3:15 PM EDT
Session Number: 3465
Presenting Author: Jacques Van Dam, MD, PhD
Abstract Title: Orally-Administered Ustekinumab Biosimilar RT-111 Delivered Via a Robotic Pill Yields Bioavailability Comparable to Subcutaneous Injection in Canines
Session Type: Poster Session
Session Title: Animal Models of IBD: Pre-Clinical Treatment of Intestinal Inflammation
Session Date & Time: May 21, 2024 from 12:30 PM to 1:30 PM EDT
Poster No: Tu1729
Presenting Author: Kyle Horlen, DVM
Abstracts selected by the American Gastroenterological Association (AGA) for presentation at DDW will be available in a supplement to Gastroenterology. The presentations and information about DDW 2024 may be accessed at https://ddw.org/.
Posted In: RANI
